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Purpose: To investigate the expression of the myocilin gene (MYOC) in the blood of primary open angle glaucoma
(POAG) patients to determine if altered systemic expression is playing a role.
Methods: Patients (n=47) were eligible for inclusion if they met standard clinical criteria for POAG. Control subjects
(n=27) were recruited who were free from glaucoma by examination. RNA was extracted from leukocytes of patients and
controls and converted to cDNA by reverse transcriptase enzyme, and quantitative PCR was used to assess expression
levels of MYOC and the house keeping gene β-globulin (HBB). The ratio of MYOC expression to HBB expression for
POAG patients was compared to that of controls and to clinical characteristics of POAG patients.
Results: Mean gene expression values were statistically similar in POAG patients and controls for both MYOC (p≤0.55)
and HBB (p≤0.48). MYOC/HBB ratios were also statistically indistinguishable between POAG patients and controls
(p≤0.90). MYOC/HBB ratios were not significantly associated with age, sex, or ethnicity of patients within the POAG
group. Similarly, MYOC/HBB ratios were not significantly associated with clinical parameters related to POAG severity,
including maximum intraocular pressure, vertical cup-to-disk ratio, static perimetry mean deviation, or static perimetry
pattern standard deviation.
Conclusions: MYOC expression is not altered in the blood of POAG patients, unlike MYOC expression in trabecular
meshwork (TM) cultures. These results suggests that MYOC expression is not altered systemically but rather that
MYOC expression may contribute to POAG pathogenesis in specific tissues such as TM.
Glaucoma  is  one  of  the  leading  causes  of  blindness
worldwide [1,2], characterized by chronic degeneration of
axons in the optic nerve head. Primary open angle glaucoma
(POAG) is the most prevalent type of glaucoma in western
countries and has risk factors that include elevated intraocular
pressure (IOP) and age [3]. Elevated IOP is associated with
increased aqueous humor outflow resistance in the trabecular
meshwork (TM) of the eye [2], although the exact mechanism
and causative factors for this increase is unclear. Up to half of
all patients with POAG have a positive family history [4,5],
and these and other observations suggest that genetic factors
may contribute to POAG [1,6,7].
Myocilin (MYOC) was the first gene linked to POAG
[8] and is the one most studied [9]. It is located in chromosome
1, contains three exons, and codes for a largely extracellular
matrix protein. This protein has an NH2-terminal coiled region
and  a  COOH-terminal  olfactomedin  domain  [10],  but  its
function is still not well understood. To date, mutations in
MYOC  seem  most  likely  to  have  their  pathogenic  effect
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largely because of inability of the protein to fold properly
[11]. This may result in an unfolded protein response in TM
cells,  activating  a  mitochondria-independent  apoptosis
pathway which ultimately leads to cell death, breakdown of
TM  cell  structure,  obstruction  of  aqueous  humor  outflow
pathway, ocular hypertension, and ultimately the optic nerve
damage of glaucoma [12-14]. MYOC may directly impair
optic  nerve  function  when  mutated  [15];  however,  direct
evidence for this hypothesis is still lacking [11,15].
Most studies investigating MYOC expression in POAG
have employed human cultured TM cells [16,17]. However,
whole  blood  gene  expression  studies  have  been  used  to
investigate POAG [18], other hereditary optic neuropathies
[19], and diseases affecting brain anatomy and function [20,
21] because the target tissues for these diseases is not readily
available. Therefore, the current study investigated MYOC
expression in whole blood from POAG patients in hope that
this approach will add to our knowledge of whether altered
systemic  expression  of  this  gene  contributes  to  POAG
pathogenesis.
METHODS
Patients and controls: Patients (n=47) were evaluated in the
Glaucoma Service at the Wills Eye Institute, Philadelphia, PA,
and  enrolled  after  examination  by  a  glaucoma  specialist.
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1004Patients were eligible for inclusion if they met the following
clinical criteria for POAG [22-25]: age greater than 40 years;
intraocular pressure (IOP) ≥21 mmHg in one or both eyes
before initiation of glaucoma treatment; normal-appearing,
open anterior chamber angles bilaterally by gonioscopy; optic
nerve appearance characteristic of the optic discs typically
observed in primary open-angle glaucoma (with localized
narrowing  or  absence  of  the  neuro-retinal  rim,  with  the
amount of cupping exceeding the amount of pallor of the rim,
and with asymmetric cupping of the optic discs in the two
eyes);  and  static  visual  field  (using  a  full  threshold  24–2
program; Humphrey Field Analyzer II; Carl Zeiss Meditec,
Inc., Dublin, CA) showing abnormalities typical of glaucoma
(as  per  Advanced  Glaucoma  Intervention  Study  criteria)
[26]. Good agreement was required between the appearance
of  the  optic  disc  and  the  visual  field.  Exclusion  criteria
included historical, neuroimaging, or biochemical evidence of
another possible optic neuropathic process affecting either
eye, significant visual loss in both eyes not associated with
glaucoma,  or  choosing  not  to  participate.  This  research
adhered to the tenets of the Declaration of Helsinki, and all
patients and controls signed an informed consent approved by
the Wills Eye Institute institutional review board.
All  control  subjects  (n=27),  frequently  spouses  of
patients, had full ophthalmologic examinations documenting
IOPs that were <21 mmHg and symmetric in the two eyes,
normal anterior chambers, optic discs that were normal and
symmetric in appearance, entirely normal static perimetry
OU, and no prior history of glaucoma. All controls had static
perimetry performed in the same fashion as POAG patients.
DNA testing: Five ml of peripheral blood were collected in
EDTA tubes from all participating individuals. DNA was
extracted using the Illustra blood genomic Prep Mini Spin Kit
from GE Healthcare (Buckinghamshire, UK), and stored at
−20 °C in aliquots until required.
All patient and control DNA samples were tested for
mutations in MYOC and its promoter. Successfully amplified
fragments were sequenced in both directions using the M13
forward and reverse primers and the BigDye terminator v3.1
cycle sequencing kit (Applied Biosystems, Foster city, CA).
Fragments were then run on the 3130xl Genetic Analyzer
(Applied Biosystems) according to the manufacturer protocol.
All sequenced fragments were then analyzed using SeqScape
software  v2.6  (Applied  Biosystems).  Table  1  details  the
sequence of the primers used the PCR annealing temperature
and the expected amplicon size.
Quantitative RT–PCR: A two-step semi-quantitative reverse
transcriptase  polymerase chain reaction (RT–PCR) method
was used to measure gene expression levels of MYOC and β-
globulin  (HBB)  in  POAG  patients  and  controls.  Random
hexameres were used as primers in the first step of cDNA
synthesis.  Total  RNA  (1  μg)  was  combined  with  0.5  μg
primers, 200 μM dNTPs, and sterile Milli-Q water (Millipore,
Billerica, MA) and preheated at 65 °C for 2 min to denature
secondary structures. The mixture was then cooled rapidly to
20 °C and then 10 μl 5× RT Buffer, 10 mM dithiothreitol, and
200  U  Moloney  Murine  Leukemia  Virus  Reverse
Transcriptase (Invitrogen Life Sciences, Grand Island, NY)
were added for a total volume of 50 μl. The RT mix was
incubated at 37 °C for 90 min then stopped by heating at 95 °C
for 5 min. The cDNA stock was stored at −20 °C.
Relative  RT–PCR  was  performed  to  measure  gene
expression  of  MYOC  and  HBB  according  to  standard
guidelines [27]. Primer sequences and optimal PCR annealing
temperatures (ta) are listed in Table 2. Primer sequences were
designed to span intron regions to insure that no false positive
PCR fragments would be generated from pseudogenes and
contaminate genomic DNA. In addition, all forward PCR
primers  were  labeled  with  fluorescein  (6-FAM),  making
quantitation more accurate. Polymerase chain reactions were
performed  using  100  ng  of  cDNA,  5  pmoles  of  each
oligonucleotide primer, 200 μM of each dNTP, 1 unit of
HotStar Taq-polymerase (Qiagen, Valencia, CA) and 1× PCR
buffer in a 20 μl volume. The PCR program initially started
with a 95 °C denaturation for 5 min, followed by 25 cycles of
95 °C for 1 min, ta °C for 45 s, and 72 °C for 1 min. Linear
amplification range for each gene was tested on the adjusted
cDNA,  and  25  cycles  were  found  to  be  optimal  for  both
TABLE 1. PRIMER SEQUENCES, PCR ANNEALING TEMPERATURE AND AMPLICON SIZE FOR THE MYOCILIN GENE.
Exon Primer sequence Annealing
temp (°C)
Amplicon size
(bp)
Pro-F TGTAAAACGACGGCCAGTGCTGGCTGTTATTTTTCTCTGT 55 592
Pro-R CAGGAAACAGCTATGACCCAGAAGCAGCAGCTGGACA    
1F TGTAAAACGACGGCCAGTCACCCATCCAGGCACCTC 57 775
1R CAGGAAACAGCTATGACCGAGCGCCTGTAGCAGGTCA    
2F TGTAAAACGACGGCCAGTTGGCCGGCAGCCTATTTA 57 325
2R CAGGAAACAGCTATGACCTGGGTGGGCATTTACCCTAT    
3AF TGTAAAACGACGGCCAGTCATCTACTGGCTCTGCCAAG 57 850
3AR CAGGAAACAGCTATGACCAAGTTGTCCCAGGCAAAGAG    
3BF TGTAAAACGACGGCCAGTTGACTACAACCCCCTGGAGA 57 700
3BR CAGGAAACAGCTATGACCCTGCAATCACATCTCCCAAC    
          F=forward; R=reverse; Pro – promoter. Bold and underlined sequences are those of the M13.
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1005MYOC and HBB. The PCR samples were electrophoresed on
the 3130xl Genetic Analyzer (Applied Biosystems).
Statistical analysis: Absolute RT–PCR values were used to
calculate a ratio of the MYOC peak area in the selected linear
amplification  cycle  divided  by  that  of  HBB,  creating  an
MYOC/HBB ratio. All clinical and genetic data were analyzed
using SPSS v17 (IBM, Chicago, IL).
RESULTS
Age (POAG patients 67.3 years; controls 63.6 years; p≤0.17)
and sex (POAG 26 males/21 females; controls 12/15; p≤0.18)
of the 47 unrelated POAG patients were similar to the 27
control individuals, but ethnicity differed between the POAG
group (25 Caucasian/22 African American) and the control
group (23 Caucasian/4 African American; p≤0.003).
After aligning and reading all sequences neither POAG
patients  nor  controls  were  found  to  have  any  significant
mutation or polymorphism in the coding or promoter regions
of MYOC.
Mean gene expression values for both MYOC and HBB
(p≤0.48)  were  statistically  similar  in  POAG  patients  and
controls (Table 3). MYOC/HBB ratios (p≤0.90) were also
indistinguishable  between  POAG  patients  and  controls.
Because of ethnic differences between the POAG group and
controls,  gene  expression  values  and  ratios  were  also
compared between Caucasian POAG patients and Caucasian
controls. Mean MYOC (p≤0.90) gene expression and MYOC/
HBB (p≤0.54) ratios also did not differ between these groups.
MYOC/HBB ratios were not significantly associated with
age, sex, or ethnicity of patients within the POAG group
(Table 4). Similarly, MYOC/HBB ratios were not significantly
associated with clinical parameters related to POAG severity,
including maximum intraocular pressure, vertical cup-to-disk
ratio,  static  perimetry  mean  deviation,  or  static  perimetry
pattern  standard  deviation.  Power  calculations  indicate  a
power ≤80% on these tests, leaving open the possibility of
false negative type II statistical errors.
DISCUSSION
The 47 patients reported here met rigorous clinical criteria for
POAG [22-25] with elevated IOP, normal anterior chamber,
and  evidence  on  funduscopic  exam  and  visual  fields  of
glaucomatous  optic  nerve  damage.  They  did  not  have
evidence of other types of glaucoma or alternative causes of
optic  nerve  injury  by  clinical  criteria,  and  none  had
dysmorphism or an obvious genetic syndrome. They were
compared to 27 control individuals in whom POAG and other
evidence of optic nerve damage were carefully excluded.
Screening the full MYOC gene and its promoter region
revealed no mutations or significant polymorphisms in POAG
patients or controls. These results are not surprising, since the
prevalence of MYOC mutations is generally less than 5% in
adult  POAG  populations  [28].  Currently,  there  are  85
glaucoma  causing  mutations  listed  in  the  comprehensive
myocilin  database.  They  were  classified  as  a  glaucoma
causing mutations based on the following criteria: i) predicted
disruption of protein translation (e.g., frame-shift mutations
and premature stop codons); ii) sequence variant frequency in
control (unaffected) populations (those with a frequency >1%
were classified as polymorphisms); iii) variant location (i.e.,
protein  homology  domain;  cross  species  conservation  of
coding sequence); iv) evidence for partial segregation with the
phenotype within a family and v) results of solubility studies.
Interestingly, several sequence changes have been reported in
the MYOC promoter region, but they were defined as neutral
polymorphisms  based  on  the  pathologic  characteristics
TABLE 2. PRIMER SEQUENCES AND ANNEALING TEMPERATURE β-GLOBULIN AND MYOCILIN FLUORESCENT LABELED PRIMERS.
Primer name Primer sequence Annealing temp (°C)
β-globulin-F (6-FAM)AGCCTCGCCTTTGCCGA 57
β-globulin-R CTGGTGCCTGGGGCG  
MYOC-LAB-F (6-FAM)TTTCTACGTGGAATTTGGACA 59
MYOC-R GTAGGTGGGCTTGGGGTCT  
          F=forward; R=reverse. The forward primers were labeled with 6-FAM.
TABLE 3. MYOCILIN GENE EXPRESSION IN POAG PATIENTS AND CONTROLS.
Parameter Number POAG:control POAG Control p≤
MYOC expression; mean (SD) 47:26 7476 (4325) 6839 (4271) 0.55
β-globulin expression; mean (SD) 44:24 109533 (31355) 103885 (31047) 0.48
MYOC/β-globulin; mean (SD) 42:23 0.0685 (0.0520) 0.0667 (0.0597) 0.90
MYOC expression in Caucasians; mean (SD) 26:22 7132 (4526) 7268 (4121) 0.90
β-globulin expression in Caucasians; mean (SD) 22:20 104941 (31552) 99392 (32171) 0.58
MYOC/β-globulin in Caucasians; mean (SD) 21:19 0.0622 (0.0487) 0.0730 (0.0619) 0.54
          POAG=primary open angle glaucoma; MYOC=myocilin gene expression; SD=standard deviation.
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1006described  above  (myocilin).  This  may  indicate  that  the
promoter region is free of mutations which could alter its
expression. Alternatively, assessing potential pathogenicity
for promoter region sequence changes can be challenging and
may not follow the same pathological criteria as sequence
changes found in coding regions [29].
Expression of MYOC in blood of POAG patients was
unchanged compared to that of controls (Table 3). Expression
was  statistically  similar  to  that  of  the  housekeeping  gene
HBB,  and  the  normalized  expression  of  MYOC  (MYOC/
HBB)  also  did  not  differ  between  patients  and  controls.
MYOC  expression  did  not  differ  between  Caucasian  and
African  American  POAG  patients  and  ethnicity  matched
controls. Finally, MYOC/HBB did not correlate with age or
with various clinical factors associated with POAG such as
visual acuity, IOP, and C/D ratio (Table 4).
The lack of significant change in MYOC expression in
blood of POAG patients stands in contrast to previous studies
documenting  decreased  expression  of  MYOC  in  cultured
human TM cells [16]. Gene expression studies in whole blood
are  clearly  capable  of  documenting  changes  pertinent  to
complex neurologic diseases such as autism [30], amytrophic
lateral sclerosis [31], schizophrenia [32],and other psychoses
[33]. Patients with Leber hereditary optic neuropathy, another
spontaneous  optic  neuropathy  with  a  genetic
pathophysiology, had decreased OPA1 expression in blood
[19]. Similarly, this same POAG patient and control group
exhibited  decreased  systemic  OPA1  expression  in  blood
[18]. MYOC expression is greatest in the TM [34] and is
dramatically  induced  by  dexamethasone,  a  glucocorticoid
[17], in human TM cultures, leading to the original name for
the MYOC protein of TM inducible glucocorticoid response
element (TIGR) [35] and supporting the concept that MYOC
may  be  responsible  in  part  for  steroid-induced  glaucoma
[36].
A potential limitation of this study is that the number of
individuals  studied  was  relatively  small,  bringing  up  the
possibility that the lack of a statistical difference in MYOC
expression and MYOC/HBB ratio between POAG patients and
controls might be due to a type II statistical error because of
inadequate power. This same patient group was adequate to
confirm statistically significant differences in optic atrophy
type 1 (OPA1) expression and the OPA1/HBB ratio between
POAG  patients  and  controls  [18],  but  it  is  possible  that
differences in MYOC expression between POAG patients and
controls are smaller, although still present. Similarly, the lack
of  correlation  between  the  MYOC/HBB  ratio  and  various
clinical parameters within the POAG group may be subject to
type  II  statistical  errors.  The  population  studied  was
predominantly  Caucasian  and  African-American,  and
different results might be obtained in other ethnicities.
We  found  that  systemic  MYOC  expression  was
unchanged in these POAG patients compared to controls. One
interpretation of these results is that the MYOC protein plays
a particularly important role in the globe and that regulation
of  MYOC  expression  that  might  be  pertinent  to  POAG,
congenital  glaucoma,  and/or  steroid-induced  glaucoma  is
relatively specific to the TM and may not be reflected to a
significant extent in bone marrow or other non-ocular tissues.
It  is  also  possible  that  POAG  is  not  altered  by  wild-
type MYOC expression in any tissue [37]. A gain-of-function
disease model was suggested after identification of mutant,
misfolded forms of the MYOC protein were found aggregated
in the endoplasmic reticulum of TM cells [38]. TM cells are
essential for homeostatic regulation of aqueous humor, and
their disruption may cause elevated intraocular pressure. A
mutation-dependent,  gain-of-function  association  between
human MYOC and the peroxisomal targeting signal type 1
receptor  (PTS1R)  led  to  the  [39]  hypothesis  that  specific
MYOC mutations may cause different amounts of MYOC
TABLE 4. CORRELATION BETWEEN CLINICAL PARAMETERS AND MYOC/Β-GLOBULIN RATIOS.
Clinical parameter MYOC/β-globulin p≤
Age in years 0.204 0.21
Sex 0.040 0.81
Ethnicity 0.122 0.45
Visual acuity OD 0.016 0.92
Visual acuity OS 0.075 0.64
Maximum IOP OD 0.114 0.48
Maximum IOP OS 0.237 0.14
Vertical c/d ratio OD 0.129 0.43
Vertical c/d ratio OS 0.171 0.29
MD OD −0.042 0.80
MD OS −0.025 0.88
PSD OD 0.211 0.19
PSD OS 0.024 0.89
        MYOC/β-globulin column contains correlation coefficients; OD=right eye; OS=left eye; IOP=intraocular pressure; c/d=cup to
        disk; MD=Humphrey visual field mean deviation; PSD=Humphrey visual field pattern standard deviation.
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1007misfolding,  with  corresponding  varying  degrees  of
recognition by the ubiquitin degradation pathway. A greater
opportunity for mutant MYOC to interact with PTS1R may
allow  for  poorer  clearance  from  the  TM  endoplasmic
reticulum and greater trabecular cell dysfunction, culminating
in a higher IOP phenotype [39].
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